Dallah Healthcare Company Just Beat EPS By 11%: Here's What Analysts Think Will Happen Next

The third-quarter results for Dallah Healthcare Company (TADAWUL:4004) were released last week, making it a good time to revisit its performance. Revenues ر.س1.1b disappointed slightly, at8.6% below what the analysts had predicted. Profits were a relative bright spot, with statutory per-share earnings of ر.س1.40 coming in 11% above what was anticipated. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

After the latest results, the eight analysts covering Dallah Healthcare are now predicting revenues of ر.س4.53b in 2026. If met, this would reflect a major 20% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to expand 17% to ر.س6.22. Yet prior to the latest earnings, the analysts had been anticipated revenues of ر.س4.54b and earnings per share (EPS) of ر.س6.22 in 2026. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.

See our latest analysis for Dallah Healthcare

The analysts reconfirmed their price target of ر.س142, showing that the business is executing well and in line with expectations. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. Currently, the most bullish analyst values Dallah Healthcare at ر.س175 per share, while the most bearish prices it at ر.س106. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. The period to the end of 2026 brings more of the same, according to the analysts, with revenue forecast to display 16% growth on an annualised basis. That is in line with its 18% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 13% annually. So it's pretty clear that Dallah Healthcare is forecast to grow substantially faster than its industry.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Dallah Healthcare going out to 2027, and you can see them free on our platform here..

You still need to take note of risks, for example - Dallah Healthcare has 1 warning sign we think you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.